Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer Suppl figure 1

This study was funded by the National Natural Science Foundation for Young Scientists of China (grant no. 82103339) and the Medical Scientific Research Foundation from the Health Commission of Jiangxi Province, China (no. 202210473). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.